FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washingto

D.C. 20540	-
on, D.C. 20549	OMB APPROVAL
	UIVID APPROVAL

- 1	0.11.2 / 11 / 13								
	OMB Number:	3235-0287							
	Estimated average burden								
	hours por rosponso:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     SOUTHWELL DAVID P					2. Issuer Name and Ticker or Trading Symbol  TScan Therapeutics, Inc. [ TCRX ]							(Che	S. Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner     Officer (give title Other (specify)				
(Last)	,	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 07/25/2022							7	below)		below)	specify	
C/O TSCAN THERAPEUTICS, INC.				0112512622									E	., 6 0111661			
830 WIN	ITER STRE	EET		L													
(Street)				—   4.	If Amendment, Date of Original Filed (Month/Day/Year)					Line	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person						
WALTH	AM M	IA	02451									-   -	_	•	teporting Perso than One Repo		
,													Person	ed by More t	nan One Repo	ung	
(City)	(S	tate)	(Zip)														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			Transaction te onth/Day/	Execution Date,		3. Transaction Code (Instr. 8)  4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4)				5. Amoun Securities Beneficia Owned Fo	Form lly (D) (D) (I) (I	. Ownership orm: Direct D) or Indirect ) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code	v	Amount	nt (A) or (D)		Transacti	Transaction(s) (Instr. 3 and 4)		(11301. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code V (A) (D) Exercisable Date Title of Shares														
Stock Option (Right to Buy)	\$3.27	07/25/2022		A		100,000		(1)	0	7/24/2032	Voting Common Stock	100,000	\$0.00	100,000	D		

## **Explanation of Responses:**

1. The shares subject to this option vest over 4 years of service following July 25, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.

## Remarks:

/s/ David P. Southwell

07/27/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.